Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07276802
PHASE4

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

Sponsor: Research Insight LLC

View on ClinicalTrials.gov

Summary

A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.

Key Details

Gender

All

Age Range

22 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-04-01

Completion Date

2027-01-31

Last Updated

2026-03-31

Healthy Volunteers

No

Interventions

DRUG

Triamcinolone (Optional)

triamcinolone 40mg/ml or topical clobetasol 0.05% with nepafenac 0.3% QD for 14 days

DRUG

control group

topical medication regimen will include prednisolone acetate 1% QID, ketorolac 0.5% QID, and moxifloxacin 0.5% topical drops QID.

Locations (1)

Harvard Eye Associates

Laguna Hills, California, United States